genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Medivation
A-Lists
Top 10 M&A Deals of 2016
Industry News
Pfizer to Acquire Medivation for $14B
Industry News
Sanofi Confirms $9.3B Offer for Medivation
Cancer
NanoString, Medivation, and Astellas to Develop Breast Cancer CDx
A-Lists
Nine Takeover Targets of 2015
Cancer
Medivation Acquires Talazoparib Rights from BioMarin for Up to $570M+
News
Pfizer, Medivation Nix Development of Alzheimer Disease Therapy
News
Phase III Failure Leads Medivation and Pfizer to Ditch Dimebon for Huntington Disease
News
Pfizer and Medivation’s Alzheimer Drug Fails in First Phase III Trial
News
Pfizer Shells Out $225M for Medivation’s Late-Stage Drug
Scroll Up
Scroll Up
